Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02084095
Other study ID # 28332
Secondary ID
Status Completed
Phase
First received
Last updated
Start date March 2014
Est. completion date March 1, 2019

Study information

Verified date August 2019
Source Carol Davila University of Medicine and Pharmacy
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Background Glucose metabolism abnormalities are frequent in acromegaly. Insulin resistance (IR) correlates with the intensity of acromegaly and Insulin-like Growth factor-I (IGF-I) correlates better with IR than growth hormone (GH). Insulin secretion (IS) is significantly reduced in hyperglycemic acromegalics as compared with those with normal glucose levels. IS is independent of acromegaly intensity.

The aim of this study is to show that in active acromegaly: 1) IGF-I does not cause IR but is just a better marker of acromegaly intensity than GH; 2) high GH levels induce IR through free fatty acids (FFA); 3) hyperglycemia is caused by a defficient IS on a background of IR.

Methods Intensity of acromegaly will be assessed using serum levels of GH, IGF-I and IGF binding globulin-3. IR and IS will be assessd using an intravenous glucose tolerance test acording to Bergman model. FFA will be directly measured in plasma.


Recruitment information / eligibility

Status Completed
Enrollment 16
Est. completion date March 1, 2019
Est. primary completion date March 1, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- active acromegaly based on following criteria: minimum GH in oral glucose tolerance test (OGTT) over 1 ng/mL and serum IGF-I over upper limit of normal for age and sex

- age between 18 and 65 years old

Exclusion Criteria:

- more than one previous pituitary surgical intervention for acromegaly

- present medical treatment for acromegaly (somatostatin analogs, GH-receptor blockers, dopaminergic agonists)

- previous pituitary radiotherapy

- present medical treatment for hyperglycemia (oral antidiabetic drugs, insulin, etc)

- pituitary failure, treated or not

- medical or surgical conditions which, in the oppinion of the principal investigator, could impact on study results or patient's safety

- fasting blood glucose over 200 mg/dL or HbA1c over 8%.

- body mass index less than 20 or over 35 kg/mp

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Romania "C. I. Parhon" Institute of Endocrinology Bucharest

Sponsors (1)

Lead Sponsor Collaborator
Carol Davila University of Medicine and Pharmacy

Country where clinical trial is conducted

Romania, 

Outcome

Type Measure Description Time frame Safety issue
Primary The correlation coefficient between IGFBP-3 and insulin resistance assessed using Bergman model is non-inferior to the correlation coefficient between IGF-I and insulin resistance 2 years
Primary Free fatty acids correlates significantly with insulin resistance assessed using Bergman model 2 years
Primary Disposition index calculated using Bergman model is significantly reduced in subjects with glucose intolerance than in subjects with normal glucose tolerance 2 years
Secondary GH, IGF-I and IGFBP-3 significantly correlates with insulin resistance calculated using Bergman model 2 years
Secondary GH, IGF-I and IGFBP-3 significantly correlates with free fatty acids 2 years
Secondary GH, IGF-I and IGFBP-3 does not correlate with insulin sensitivity calculated using Bergman model 2 years
Secondary GH, IGF-I and IGFBP-3 does not correlate with disposition index 2 years
Secondary Disposition index after reduction of acromegaly activity by various treatments 3 months after surgery or start of medical treatment
See also
  Status Clinical Trial Phase
Recruiting NCT06344650 - Cellular, Molecular and Clinical Determinants of Bone Strength in in Vivo and Human Models of GH Excess. Cross-sectional and Prospective Study
Active, not recruiting NCT02092129 - Pituitary Histopathology and Hyperprolactinaemia and Risk of Glucose Metabolic Disturbances in Acromegaly. N/A
Completed NCT02012127 - Description of Sign-and-symptom Associations at Acromegaly Diagnosis.
Active, not recruiting NCT01265121 - Sleep Apnea Syndrome on Acromegaly: Impact of the Treatment on the Carbohydrates Metabolism. N/A
Terminated NCT00765323 - Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly Phase 3
Completed NCT00500227 - Predictive Factors of Response to Somatostatin Analogues in Acromegalic Patients With Persistent Disease Following Surgery
Completed NCT00531908 - Physiopathology of Sodium Retention in Acromegaly N/A
Completed NCT01278342 - Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients Phase 4
Active, not recruiting NCT01809808 - A Prospective Study of Outcome After Therapy for Acromegaly
Completed NCT00145405 - Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction Phase 4
Completed NCT00210457 - Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients Phase 3
Recruiting NCT05401084 - Diet in the Management of Acromegaly N/A
Recruiting NCT00005100 - Measurement of Outcome of Surgical Treatment in Patients With Acromegaly N/A
Completed NCT00521300 - Preoperative Octreotide Treatment of Acromegaly Phase 4
Completed NCT03548415 - Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands Phase 2
Not yet recruiting NCT04066569 - Reproducibility and Utility of OGTT in Acromegaly N/A
Not yet recruiting NCT05298891 - Hypoproteic Diet in Acromegaly N/A
Recruiting NCT04520646 - A Pilot Study of Empagliflozin in the Treatment of Acromegalic Cardiomyopathy N/A
Not yet recruiting NCT04529356 - The TMS Treatment for Postoperative Headache in GH Tumor N/A
Active, not recruiting NCT03252353 - Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly Phase 3